Spironolactone use in resistant hypertension

Carl, Dan; Sica, Domenic A.

doi:10.1007/s11906-007-0054-y

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 The reduction in systolic blood pressure after placebo subtraction is greater than expected for add-on therapy but less than what has been reported for spironolactone in observational studies. 38, 39 The study design, strict entry criteria, and representative population are strengths of the study, which suggests that half of patients with resistant hypertension will reach their blood pressure goal if darusentan is added to their existing treatment regimen.…”

Section: Efficacy and Safety Of Darusentan: A Novel Endothelin Receptmentioning

confidence: 99%

Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist

Epstein

2008

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Efficacy and Safety Of Darusentan: A Novel Endothelin Receptmentioning

confidence: 99%

Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist

Epstein

2008

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…By contrast, the fourth drug to be added to the triple regimen is still controversial and guided by empirical choices or personal preferences. Recent studies suggest the emerging role of spironolactone as the first‐line fourth drug for treating ReHy . Conversely, because of the pathophysiological rationale, others have proposed the use of β‐blockers or even centrally acting agents for managing sympathetic hyperactivity .…”

Section: Introductionmentioning

confidence: 99%

Resistant Hypertension Optimal Treatment Trial: A Randomized Controlled Trial

Investigators¹,

Krieger²,

Drager³

et al. 2013

Clinical Cardiology

View full text Add to dashboard Cite

The prevalence of resistant hypertension (ReHy) is not well established. Furthermore, diuretics, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and calcium channel blockers are largely used as the first 3-drug combinations for treating ReHy. However, the fourth drug to be added to the triple regimen is still controversial and guided by empirical choices. We sought (1) to determine the prevalence of ReHy in patients with stage II hypertension; (2) to compare the effects of spironolactone vs clonidine, when added to the triple regimen; and (3) to evaluate the role of measuring sympathetic and renin-angiotensin-aldosterone activities in predicting blood pressure response to spironolactone or clonidine. The Resistant Hypertension Optimal Treatment (ReHOT) study (ClinicalTrials.gov NCT01643434) is a prospective, multicenter, randomized trial comprising 26 sites in Brazil. In step 1, 2000 patients will be treated according to hypertension guidelines for 12 weeks, to detect the prevalence of ReHy. Medical therapy adherence will be checked by pill count monitoring. In step 2, patients with confirmed ReHy will be randomized to an open label 3-month treatment with spironolactone (titrating dose, 12.5-50 mg once daily) or clonidine (titrating dose, 0.1-0.3 mg twice daily). The primary endpoint is the effective control of blood pressure after a 12-week randomized period of treatment. The ReHOT study will disseminate results about the prevalence of ReHy in stage II hypertension and the comparison of spironolactone vs clonidine for blood pressure control in patients with ReHy under 3-drug standard regimen.

show abstract

“…On the downside, spironolactone has side-effects, such as gynecomastia, sexual dysfunction and hyperkalemia in about 10% patients given the drug. More recently eplerenone has appeared; it is a more specific blocker of aldosterone receptors with a much reduced side-effect profile, and, like spironolactone, improves outcomes in heart failure [6,7] and hypertension [8][9][10]. Aldosterone antagonists would thus seem to be excellent alternatives to thiazide diuretics in the treatment of hypertension.…”

mentioning

confidence: 99%

Spironolactone for all hypertensive patients?

Rosendorff¹

2010

Journal of Hypertension

View full text Add to dashboard Cite

Spironolactone use in resistant hypertension

Cited by 3 publications

References 7 publications

Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist

Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist

Resistant Hypertension Optimal Treatment Trial: A Randomized Controlled Trial

Spironolactone for all hypertensive patients?

Contact Info

Product

Resources

About